NBIX vs. PFE: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NBIX and PFE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | NBIX | PFE |
|---|---|---|
| Company Name | Neurocrine Biosciences, Inc. | Pfizer Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 13.21 billion USD | 144.30 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 23, 1996 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of NBIX and PFE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NBIX | PFE |
|---|---|---|
| 5-Day Price Return | 1.46% | 1.08% |
| 13-Week Price Return | 8.48% | 10.35% |
| 26-Week Price Return | 14.00% | -1.01% |
| 52-Week Price Return | -10.13% | -11.88% |
| Month-to-Date Return | 3.90% | 8.97% |
| Year-to-Date Return | -2.40% | -4.33% |
| 10-Day Avg. Volume | 0.84M | 36.18M |
| 3-Month Avg. Volume | 1.17M | 43.39M |
| 3-Month Volatility | 23.38% | 23.66% |
| Beta | 0.21 | 0.50 |
Profitability
Return on Equity (TTM)
NBIX
13.22%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, NBIX’s Return on Equity of 13.22% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
PFE
11.96%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
PFE’s Return on Equity of 11.96% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
NBIX
13.88%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
NBIX’s Net Profit Margin of 13.88% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
PFE
16.85%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
PFE’s Net Profit Margin of 16.85% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
NBIX
19.72%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
NBIX’s Operating Profit Margin of 19.72% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
PFE
18.62%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
PFE’s Operating Profit Margin of 18.62% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NBIX | PFE |
|---|---|---|
| Return on Equity (TTM) | 13.22% | 11.96% |
| Return on Assets (TTM) | 9.39% | 5.08% |
| Net Profit Margin (TTM) | 13.88% | 16.85% |
| Operating Profit Margin (TTM) | 19.72% | 18.62% |
| Gross Profit Margin (TTM) | 98.49% | 73.96% |
Financial Strength
Current Ratio (MRQ)
NBIX
3.20
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
NBIX’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
PFE
1.16
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
PFE’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
NBIX
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
NBIX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
PFE
0.70
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
PFE’s Debt-to-Equity Ratio of 0.70 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NBIX
6.75
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
NBIX’s Interest Coverage Ratio of 6.75 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
PFE
7.89
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
PFE’s Interest Coverage Ratio of 7.89 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NBIX | PFE |
|---|---|---|
| Current Ratio (MRQ) | 3.20 | 1.16 |
| Quick Ratio (MRQ) | 3.10 | 0.85 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.70 |
| Interest Coverage Ratio (TTM) | 6.75 | 7.89 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
PFE
6.65%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 6.65%, PFE offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
PFE
89.67%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
PFE’s Dividend Payout Ratio of 89.67% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NBIX | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 6.65% |
| Dividend Payout Ratio (TTM) | 0.00% | 89.67% |
Valuation
Price-to-Earnings Ratio (TTM)
NBIX
37.70
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
NBIX’s P/E Ratio of 37.70 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
PFE
13.48
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, PFE’s P/E Ratio of 13.48 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
NBIX
5.23
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
NBIX’s P/S Ratio of 5.23 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
PFE
2.27
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
PFE’s P/S Ratio of 2.27 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
NBIX
4.62
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
NBIX’s P/B Ratio of 4.62 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
PFE
1.55
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
PFE’s P/B Ratio of 1.55 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | NBIX | PFE |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 37.70 | 13.48 |
| Price-to-Sales Ratio (TTM) | 5.23 | 2.27 |
| Price-to-Book Ratio (MRQ) | 4.62 | 1.55 |
| Price-to-Free Cash Flow Ratio (TTM) | 24.84 | 10.63 |